Skip to main content

AB International Health Care Portfolio

AB International Health Care Portfolio is an equity fund managed by AllianceBernstein in the Sektor – Helse category.

About this fund

AB International Health Care Portfolio is an equity fund run by AllianceBernstein, compared against the Sektor – Helse peer group.

The fund: 43 years of track record, running since 1983 (share classes may be younger).

The fund has been in Vinay Thapar's hands since 2013 — 13 years.

Measured on return so far this year measured in NOK as of 13.11.2026, the fund is number 6 of 18 in its category.

It is measured against MSCI World Health Care Index - Unhedged to USD.

Manager
AllianceBernstein
Category
Sektor – Helse
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
LU0058720904
Inception
1983-07-20
Benchmark
MSCI World Health Care Index - Unhedged to USD
AUM
3.5 bn USD
Returns
YTD 10.5% · 1Y 11.9% · 3Y 4.7% · 5Y 6.8%

Portfolio managers

Actively managedEquityGlobalHealth care
YTD Return · NOK
+10,5 %from NAV
Calculated NOK return from USD · Base (NOK Calculated)
Last NAV 690,35 USD · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+10,5 %
YTD
+11,9 %
1y
+4,7 %
3y, annualised
+6,8 %
5y, annualised
+12,1 %
10y, annualised
Fund size
3,5 mrd. USD
Total fund AUM
Management fee
1,75 %
Annual · class Standard
Ongoing charge
1,96 %
Annual · class Standard
Performance fee
None
Stated by the manager
Annual cost on platforms
1,27 %–1,49 %
Class Standard · 3 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Jul 1983
ISIN LU0058720904
BenchmarkMSCI World Health Care Index - Unhedged to USD
About the fund
The fund

AB International Health Care Portfolio is an actively managed global health care equity fund with history back to 1983. It is managed by AllianceBernstein (AB), a US asset manager headquartered in Nashville and majority-owned by Equitable Holdings.

Investment philosophy

The managers look for companies with a history of high returns on invested capital and strong free cash flow. They emphasise companies expected to capture health care spending, either through new treatments and therapies or by offering customers lower costs.

The managers

Responsibility is shared between Vinay Thapar in New York and Jane Bleeg in London. Thapar has managed the fund since 2013. He joined AB in 2011, is co-chief investment officer for US Growth Equities and also manages AB American Growth Portfolio. His background includes biotech research at Bear Stearns and health care analysis at American Century, and he holds a bachelor's degree in biology. Bleeg has managed the fund since 2025. She joined AB in 2016 and became portfolio manager for European Value Equities in 2022. Before that she was a senior analyst covering European health care and large US pharmaceutical companies. She also has a background from a health care hedge fund, investment banking and life science consulting.

The portfolio

The portfolio has fewer positions than comparable funds but a lower active share, so it deviates less from its benchmark than typical active health care funds. Pharmaceuticals and biotechnology are lasting centres of gravity, and the United States is the largest country. Companies such as Eli Lilly, Novartis and Roche recur among the larger positions. The fund has fluctuated less than comparable funds.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

VI
Portfolio Manager
On the fund since Apr 1, 2013
JA
Portfolio Manager
On the fund since May 1, 2025

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#6/ 18Year to date
+10.48% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#9/ 221 year
+11.93% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#19/ 223 years (ann.)
+4.34% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#12/ 225 years (ann.)
+6.80% NOK

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data